Company Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally.
The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.
It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency.
The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity.
The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015.
Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2008 |
| IPO Date | Oct 5, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 414 |
| CEO | David Meeker |
Contact Details
Address: 222 Berkeley Street, 12th Floor Boston, Massachusetts 02116 United States | |
| Phone | 857 264 4280 |
| Website | rhythmtx.com |
Stock Details
| Ticker Symbol | RYTM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001649904 |
| CUSIP Number | 76243J105 |
| ISIN Number | US76243J1051 |
| Employer ID | 46-2159271 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David P. Meeker M.D. | Chairman, President and Chief Executive Officer |
| Hunter C. Smith M.B.A. | Chief Financial Officer and Treasurer |
| Dr. Alastair Garfield Ph.D. | Chief Scientific Officer |
| Yann Mazabraud | Executive Vice President and Head of International |
| Jennifer Lee | Executive Vice President and Head of North America |
| Joseph Shulman | Chief Technical Officer |
| David Connolly | Head of Investor Relations and Corporate Communications |
| Jim Flaherty | Senior Vice President and General Counsel |
| Sarah Ryan | Vice President of Sales and Marketing |
| Pamela J. Cramer | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 5, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 5, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 5, 2026 | 10-Q | Quarterly Report |
| May 5, 2026 | 8-K | Current Report |
| Apr 30, 2026 | SCHEDULE 13G | Filing |
| Apr 29, 2026 | ARS | Filing |
| Apr 29, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 3, 2026 | 8-K | Current Report |
| Mar 27, 2026 | SCHEDULE 13G/A | Filing |